← Eli Lilly and overview

Eli Lilly and vs US Dollar/Japanese Yen FX Spot Rate: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Eli Lilly and Company (LLY)

Q3 2026
▲2▼2

Lilly hits $1T on obesity demand, but competition and coverage risks rise

  • Obesity drug demand drives record revenue and $1T valuation Revenue jumped 47.7% to $22.97 billion, with Mounjaro sales up 91%, pushing Lilly past a $1 trillion market value. The company raised its financial guidance, showing the obesity-drug boom is still accelerating.

    This is the core positive force behind Lilly's price surge in Q3.

  • Pipeline and access expand Lilly acquired AtaiBeckley, reported positive Alzheimer's data, won cancer and insulin approvals, and expanded access to its oral GLP-1 Foundayo through Amazon and CVS. A new $6.5 billion Houston plant will boost supply.

    These moves broaden Lilly's product lineup and make its drugs easier to get, supporting future growth.

  • Competition intensifies as Novo Nordisk scores wins Novo Nordisk won EU approval for oral Wegovy, and its CagriSema beat Zepbound in a head-to-head trial (12.4% vs. 9.1% weight loss). This threatens Lilly's dominance in the obesity market.

    Rising competition is a key risk that could pressure Lilly's market share and pricing.

  • Regulatory and coverage headwinds mount Retatrutide's FDA filing slipped to 2027 due to a heart-event imbalance, Germany's rebate reform led to manufacturing cuts, and about 14% of US employers plan to drop GLP-1 coverage by 2027.

    These setbacks could delay a key drug and reduce future sales, weighing on investor sentiment.

September 2026
▲3▼1

Lilly hits $1T on obesity drug strength, but Novo's rival shows better weight loss

  • Lilly crosses $1 trillion market value Eli Lilly became a $1 trillion company, powered by its obesity drugs. Mounjaro sales jumped 91% and overall quarterly revenue rose 47.7%, showing the huge demand for its weight-loss and diabetes treatments.

    This milestone reflects the core driver of Lilly's valuation and investor enthusiasm during the period.

  • New oral pill Foundayo gains traction Lilly launched its oral GLP-1 pill Foundayo in the UK, and it captured about a third of new US oral GLP-1 patients. This expands Lilly's reach beyond injections and taps into patient preference for pills.

    Foundayo's uptake is a new product-level success that broadens Lilly's obesity franchise.

  • Pipeline and manufacturing advances Lilly won FDA approvals for a breast cancer combo and weekly insulin Onswik, closed the AtaiBeckley deal, and broke ground on a $6.5 billion Houston plant. These moves strengthen its long-term growth and supply capacity.

    These are concrete new developments that support future revenue and production scale.

  • Novo's CagriSema beats Zepbound in trial Novo Nordisk's CagriSema helped patients lose 12.4% weight versus 9.1% for Lilly's Zepbound/tirzepatide in a head-to-head trial. If approved, this could slow Lilly's market-share gains in obesity.

    This competitive threat is a key counterweight to Lilly's positive momentum.

Latest
▲3▼1

Lilly's pipeline wins and Foundayo growth offset Novo's competitive threat

  • Foundayo captures one-third of new oral GLP-1 patients Lilly's oral weight-loss pill Foundayo now accounts for about one-third of new patients starting oral GLP-1 medicines, with market share rising weekly. This shows real commercial traction, supporting future sales growth and reinforcing Lilly's obesity franchise.

    Demonstrates Foundayo's rapid adoption, a key growth driver for Lilly's obesity business.

  • Retatrutide delivers up to 20.8% weight loss in Phase 3 Lilly's next-generation obesity drug retatrutide helped patients lose up to 20.8% of body weight in a Phase 3 trial, with many no longer meeting obesity criteria. This strengthens Lilly's pipeline and future growth prospects beyond current drugs.

    Positive clinical data for a key pipeline asset boosts long-term revenue potential.

  • Foundayo cuts cardiovascular risk in large trial Foundayo reduced heart risks by 16% versus insulin in a major trial, with lower death rates. This could expand its use to heart patients, boosting sales and differentiating it from competitors.

    Cardiovascular benefit expands Foundayo's label potential and market reach.

  • Novo's CagriSema beats Lilly's tirzepatide in head-to-head Novo Nordisk's CagriSema helped patients lose 12.4% weight versus 9.1% for Lilly's tirzepatide in a Phase 3 trial. This competitive threat could slow Lilly's market share gains if CagriSema wins approval.

    Direct competitive loss in a key trial poses a risk to Lilly's obesity leadership.

▲3▼1

Lilly's pipeline and manufacturing expand as competition intensifies

  • FDA approves new breast cancer combo The FDA granted full approval to Lilly's Inluriyo plus Verzenio for ESR1-mutated breast cancer, based on a trial where the combo doubled progression-free survival versus Inluriyo alone. This expands Lilly's oncology offerings and adds a new revenue stream, helping diversify beyond obesity drugs.

    New approval directly boosts Lilly's oncology business and revenue potential.

  • Lilly breaks ground on $6.5B Houston plant Lilly started building a $6.5 billion manufacturing site in Houston to produce active ingredients for its medicines, including the oral obesity drug Foundayo. This is part of a $50 billion U.S. investment to expand capacity and secure supply for future growth.

    Major capital investment supports long-term production capacity and supply chain.

  • Novo's CagriSema beats Zepbound in head-to-head trial In a phase 3 trial, Novo's CagriSema helped patients lose 12.4% of their weight over 60 weeks, compared to 9.1% for Lilly's Zepbound. This suggests a competitive threat in the obesity market, potentially slowing Lilly's market share gains if CagriSema wins approval.

    Direct competitive trial result could pressure Lilly's obesity franchise.

  • FDA approves once-weekly insulin Onswik The FDA approved Lilly's Onswik, a once-weekly basal insulin for type 2 diabetes, which cuts injections from daily to weekly. This strengthens Lilly's diabetes portfolio and offers a more convenient option, potentially capturing market share from daily insulins.

    New product approval expands diabetes franchise and addresses patient convenience.

▲4

Lilly's obesity lead widens as pipeline deals and analyst targets climb

  • Foundayo grabs 30% of new US oral weight-loss patients Lilly's new obesity pill Foundayo has captured over 30% of new US patients starting oral weight-loss medicines, up from almost nothing. Novo's Wegovy pill once held about 90% of that market. This shows Lilly is winning real prescriptions, not just headlines, which supports future sales.

    Concrete evidence that Lilly's newest product is taking market share, a key growth driver.

  • Citi raises Lilly target to Street-high $1,600 Citi lifted its Lilly price target to $1,600, implying about 45% upside, even after the stock fell 8% in a month. The analyst points to Lilly's dominance in obesity prescriptions, Foundayo's prescriber growth, and retatrutide's strong trial results. This boosts investor confidence.

    A major analyst upgrade directly addresses why the stock could move higher despite recent weakness.

  • Lilly completes AtaiBeckley deal for depression drug Lilly closed its acquisition of AtaiBeckley, adding BPL-003, a rapid-acting treatment for depression that resists standard therapy. This expands Lilly's neuroscience pipeline beyond obesity, using its cash to plant seeds for future growth. It reduces reliance on weight-loss drugs.

    Shows Lilly is actively diversifying into new treatment areas, a strategic positive.

  • New data and deals bolster pipeline at EASD and beyond Lilly will present strong trial data for retatrutide, Foundayo, and eloraTZP at a major diabetes conference. It also signed new research deals with QurCan and Twist Bioscience. These moves strengthen Lilly's pipeline and technology, supporting long-term growth even if they don't boost sales immediately.

    Highlights ongoing pipeline progress and partnerships that underpin future revenue.

▲4

Lilly hits $1 trillion as obesity drugs and pipeline deals drive growth

  • Lilly hits $1 trillion market cap on obesity drug strength Lilly crossed $1 trillion in market value, with Q2 revenue up 47.7% and Mounjaro sales up 91%. The obesity franchise and expanded access are powering growth, and analysts see more upside.

    This milestone reflects the scale of Lilly's success and investor confidence, directly answering why the stock is moving.

  • J.P. Morgan raises estimates on obesity drug growth J.P. Morgan lifted 2027 revenue and EPS forecasts, keeping an Overweight rating and $1,400 target. It expects incretin sales to exceed $100 billion by 2030, driven by Zepbound, Mounjaro, and Foundayo.

    Analyst upgrades signal growing confidence in Lilly's long-term growth, a key driver of stock movement.

  • Lilly launches Foundayo in UK, first European market Lilly launched its oral weight-loss pill Foundayo in the UK, the first European market. The pill costs £100-£120 per month, much less than injections, potentially widening access and boosting sales.

    This is a concrete step in expanding Lilly's obesity franchise globally, directly supporting future revenue growth.

  • Lilly builds neuroscience as new growth driver Neuroscience revenue grew 32% to $811 million in H1 2026, led by Kisunla. Acquisitions like AtaiBeckley and Centessa add pipeline assets, diversifying beyond obesity and reducing reliance on GLP-1 drugs.

    This shows Lilly's efforts to create a second growth engine, which could sustain long-term growth and attract investors.

August 2026
▲3▼1

Lilly's Q2 Beat, Pipeline Wins Offset Rising Competition and Coverage Risks

  • Q2 earnings beat and guidance raise Lilly's Q2 revenue jumped 47.7% to $22.97 billion, beating expectations, with Mounjaro and Zepbound making up 65% of sales. Management raised guidance, signaling confidence in continued momentum.

    This is the core new financial result that drove the stock in August.

  • Pipeline and access expansion Lilly widened its lead over Novo Nordisk after CagriSema disappointed. Foundayo won UK approval, cheap access expanded via Amazon and CVS, and new deals in Alzheimer's, oncology, RNA vaccines, and immunology strengthened the pipeline.

    These new developments support future growth and competitive positioning.

  • Label expansions and cost savings Mounjaro gained a heart-risk label, broadening its use, and Zepbound showed cost savings, reinforcing its value proposition. These updates could boost demand and payer acceptance.

    New label and cost data are incremental positives for the franchise.

  • Competition and coverage headwinds Novo Nordisk launched oral Wegovy in Germany and expects a fragmented obesity market. About 14% of US employers plan to drop GLP-1 coverage by 2027, which could slow US sales growth.

    These are new competitive and reimbursement risks that could pressure future sales.

▲3▼1

Lilly's heart-label win and pipeline deals widen its lead

  • FDA expands Mounjaro label to cut heart risks The FDA approved Mounjaro to lower the risk of heart attacks, strokes and heart-related death in high-risk type 2 diabetes patients. This makes the drug useful for more people, supporting sales and pricing power, though it also increases pressure on manufacturing capacity and insurance coverage.

    A new regulatory approval directly expands the market for Lilly's biggest drug.

  • Taltz plus Zepbound shows durable one-year benefit Phase 3b trials showed combining Taltz and Zepbound helped patients with psoriatic disease and obesity achieve clearer skin and more weight loss than Taltz alone after a year. This supports using Lilly drugs together, which could boost sales across both products.

    New clinical data supports broader use of two Lilly drugs together.

  • Lilly buys Merida Biosciences for up to $2.875 billion Lilly agreed to buy Merida Biosciences for up to $2.875 billion, gaining an early-stage immunology drug for Graves' disease and thyroid eye disease. This uses cash from Lilly's obesity franchise to diversify into new treatment areas, though the drug is still years from market.

    A major acquisition shows Lilly using its cash to build new growth beyond weight-loss drugs.

  • Novo launches oral Wegovy in Germany as competition builds Novo Nordisk launched its Wegovy pill in Germany, the EU's largest drug market, and expects pills to take over a third of GLP-1 use by 2030. Lilly's Foundayo pill is in Britain and targeting 40+ markets, so this is a real race for the oral obesity market.

    A direct competitor's launch in a key market threatens Lilly's share of the growing oral GLP-1 market.

▲3▼1

Lilly's GLP-1 lead widens, but employer coverage and pricing risks build

  • Zepbound shown to cut healthcare costs in older adults A real-world study found Zepbound users over 55 had up to 38% lower healthcare costs, with savings reaching $607 per patient per month by 12 months. This evidence could persuade Medicare and insurers to cover obesity drugs, supporting demand.

    This new study directly addresses payer resistance, a key risk, by showing cost savings that could expand coverage and demand.

  • 14% of US employers to drop obesity drug coverage by 2027 A survey shows about 14% of US employers plan to end GLP-1 coverage by 2027 due to rising costs, with the share covering obesity drugs already falling from 72% to 60%. This could reduce Zepbound prescriptions and slow US sales growth.

    This is a new, concrete threat to demand from a major payer group, directly countering the positive coverage narrative.

  • FDA clears Lilly-Roche Alzheimer's blood test The FDA cleared the Elecsys pTau217 blood test, developed with Roche, as the first single-biomarker test to rule in or out Alzheimer's amyloid pathology. This could expand diagnosis and boost the market for Lilly's Alzheimer's drug donanemab.

    This new approval opens a path to wider Alzheimer's diagnosis and treatment, a potential new growth area beyond GLP-1 drugs.

  • Oncology portfolio grows 11%, diversifying beyond GLP-1 Lilly's oncology revenue rose 11% to $4.84 billion in the first half, with newer drugs like Jaypirca up 66% and Inluriyo contributing $110 million. This shows Lilly is building a second growth engine, reducing reliance on obesity drugs.

    This new data highlights a broadening revenue base, which is important for long-term growth and risk reduction.

▲3▼1

Lilly's obesity franchise keeps winning as pipeline and global reach expand

  • UK approves Foundayo for weight loss and diabetes Britain cleared Lilly's once-daily weight-loss pill Foundayo for both obesity and type 2 diabetes, the first European approval. A pill is easier for patients than injections, so it opens a new market and widens Lilly's lead over Novo's rival pill.

    New regulatory approval expands Lilly's addressable market and competitive position.

  • Lilly adds Alzheimer's and ion channel deals Lilly bought rights to an early-stage Alzheimer's drug for $10 million upfront (up to $1 billion more if it works) and teamed up with OmniAb on an ion channel program worth up to $370 million. These small bets refill the pipeline beyond weight-loss drugs.

    New deals diversify Lilly's pipeline and reduce reliance on GLP-1s.

  • Lilly partners on RNA vaccines Lilly signed a research and licensing deal with Amplitude Therapeutics to develop trans-amplifying RNA vaccines for infectious diseases, with options for two more targets. It is an early-stage move into a new treatment area, using Lilly's cash to plant seeds for future growth.

    New collaboration expands Lilly's technology base into vaccines.

  • Novo CEO says obesity market won't be winner-take-all Novo Nordisk's chief said the obesity market will split among many players, like different soda brands, rather than one winner. Novo's oral Wegovy already holds 90% of the oral GLP-1 market. This is a reminder that Lilly's dominance may face limits as competition grows.

    A real counterweight: competition could cap Lilly's long-term market share.

▲4

Lilly's obesity franchise keeps winning as new markets and legal wins add up

  • UK approves Foundayo, first market outside US Britain's regulator cleared Lilly's once-daily weight-loss pill Foundayo, the first approval outside the US. This opens a new market for a pill version of its obesity drug, which could reach patients who dislike injections. It is not yet sold through the NHS while cost regulators review it.

    A brand-new regulatory approval expands Lilly's addressable market beyond the US.

  • Amazon and CVS widen cheap access to Lilly drugs Amazon Pharmacy will offer Lilly's Zepbound pen and Foundayo pill to Medicare patients for $50 a month, and CVS expanded its weight-management program with Lilly, adding app-based access and $29 clinic visits. Easier, cheaper access should lift prescription volumes.

    New distribution deals directly increase how many patients can get Lilly's drugs.

  • Lilly sues sellers of unapproved retatrutide Lilly filed six lawsuits against businesses selling unapproved versions of retatrutide, its experimental obesity drug, and has referred over 200 parties to authorities. This protects the future franchise from unsafe copycats and keeps the market ready for the real drug when approved.

    Legal action defends a key future growth driver from illicit competition.

  • Analysts raise targets on international obesity opportunity BofA lifted its Lilly price target to $1,344 and said overseas obesity sales could eventually beat the US, with most Foundayo peak sales expected abroad. Other banks also raised targets after strong Q2 results. This reflects growing confidence in Lilly's global growth runway.

    Analyst upgrades signal that the market sees more upside from international expansion.

▲4

Lilly's Q2 Beat and Raised Guidance Cement Obesity-Drug Dominance

  • Q2 beat and raised guidance Lilly reported Q2 revenue of $22.97 billion, up 47.7%, and adjusted EPS of $8.38, beating estimates by 27%. Management raised full-year revenue guidance to $85–$87 billion and EPS to $36.25. The stock jumped as much as 7% on the news, reflecting strong demand for its obesity and diabetes drugs.

    This is the core new event that directly answers why LLY is moving right now.

  • Mounjaro and Zepbound sales surge Mounjaro sales jumped 91% to $9.94 billion and Zepbound brought in $4.93 billion, together 65% of total revenue. This shows Lilly's GLP-1 franchise is still growing rapidly, driving the earnings beat and giving confidence that demand remains strong despite competition.

    It explains the fundamental driver behind the beat-and-raise and the stock's move.

  • Novo Nordisk's setback boosts Lilly's competitive edge Novo Nordisk's next-generation obesity drug CagriSema fell short of Lilly's Zepbound in blood sugar control, and Novo guided to a sales decline and cut 9,000 jobs. This strengthens Lilly's position as the clear leader in the obesity market, which supports its pricing power and long-term growth.

    It highlights a key competitive shift that benefits Lilly and is new information.

  • Retatrutide filing planned for early 2027 Lilly plans to file for approval of its next-generation obesity drug retatrutide in early 2027. The drug helped patients lose over 20% of body weight and could also treat sleep apnea and reduce heart risk. Analysts see it as a future growth driver, though it won't contribute revenue until after 2027.

    It is a new pipeline update that reinforces Lilly's long-term growth story.

July 2026
▲2▼1

Lilly hits record on obesity demand, but competition and delays loom

  • Obesity drug demand drives record results Lilly hit record highs as demand for its obesity drugs surged, with revenue jumping 55.5% to $19.8 billion and guidance raised. JPMorgan lifted its price target to $1,400, reflecting strong confidence.

    This is the core positive driver of the stock's record performance in July.

  • Pipeline expansion and strategic investments Lilly expanded its pipeline through the $3.8 billion AtaiBeckley acquisition, positive Alzheimer's data, Canadian approval for Ebglyss, U.S. manufacturing investment, and an AI drug-discovery alliance, supporting future growth.

    These moves strengthen Lilly's long-term growth prospects and diversify its business.

  • Retatrutide shows promise but faces delays Retatrutide showed strong Phase 3 weight loss, but a heart-event imbalance bears watching. Its FDA filing slipped to early 2027 due to manufacturing data gaps, delaying a key growth driver.

    This is a key pipeline update with both positive efficacy and negative regulatory delay.

  • Competition and policy headwinds intensify Germany's rebate reform prompted Lilly to scale back manufacturing there, and Novo Nordisk won EU approval for oral Wegovy, intensifying competition. These pressures could weigh on future sales and margins.

    These are significant risks that emerged in July and could impact Lilly's growth trajectory.

▲4

Lilly's GLP-1 dominance grows as pipeline and supply expand

  • Q1 revenue surges 55.5% on Foundayo launch Lilly's first-quarter revenue jumped 55.5% to $19.8 billion, beating estimates, as new oral GLP-1 Foundayo and strong Mounjaro and Zepbound sales drove growth. Management raised full-year guidance, and an analyst set a $1,365 price target, reinforcing confidence in Lilly's earnings power.

    This shows the core financial engine behind Lilly's stock and why analysts remain bullish.

  • Retatrutide Phase 3 success, FDA filing planned Lilly's next-generation obesity drug retatrutide cut weight by up to 22.6% in Phase 3 trials, with a planned FDA submission in early 2027. This strengthens Lilly's future obesity franchise, though a slight imbalance in serious heart events bears watching.

    It confirms a major future growth driver and addresses the earlier delay, showing the pipeline is back on track.

  • Lilly expands US manufacturing with Resilience Lilly and Resilience are investing $750 million to expand U.S. production of the KwikPen injectable device, creating 400 jobs and boosting supply capacity for diabetes and obesity medicines. This helps ensure Lilly can meet soaring demand and reduces reliance on foreign manufacturing.

    It directly addresses supply constraints that could limit growth and shows Lilly investing in its core business.

  • Lilly joins Illumina's AI drug discovery alliance Lilly became a foundational participant in Illumina's Billion Cell Atlas, gaining access to massive genetic data to speed AI-driven drug discovery. This long-term move could help diversify Lilly's pipeline beyond GLP-1 drugs and keep it at the forefront of biotech innovation.

    It signals a strategic push into next-generation technology that could yield new drugs and reduce reliance on one franchise.

▲1▼1

Lilly buys depression pipeline, but retatrutide filing slips to 2027

  • Lilly to buy AtaiBeckley for up to $3.8B Lilly agreed to pay $2.8 billion upfront, plus up to $1 billion more if milestones are met, for AtaiBeckley and its experimental psychedelic depression treatment. It uses Lilly's cash to add a new growth area beyond weight-loss drugs, though the upfront cost is real.

    This is the period's biggest new deal and shows how Lilly is spending its obesity-drug profits to diversify.

  • Retatrutide approval filing delayed to early 2027 Lilly pushed back its filing for next-generation obesity drug retatrutide because it needs more manufacturing and quality-control data for regulators. The drug still worked well in trials, but the delay means a key future growth driver arrives later than expected.

    This is the main new negative and directly affects Lilly's next big obesity-drug opportunity.

▼2▲1

Lilly's obesity franchise powers growth as it expands into new drug areas

  • Germany's cost reform raises rebates, Lilly to scale back manufacturing Germany passed a law forcing drugmakers to pay higher rebates, aiming to cut €16 billion in health costs. Lilly's CEO said the company will scale back manufacturing plans there, a real headwind for its European business and investment.

    A concrete regulatory setback that could hurt Lilly's sales and expansion in a major market.

  • Lilly acquires AtaiBeckley for up to $3.8 billion Lilly is buying psychedelic drugmaker AtaiBeckley for about $2.8 billion upfront plus up to $1 billion in milestones. This adds a promising treatment for resistant depression to Lilly's pipeline, showing it is using its cash to expand beyond weight-loss drugs.

    A new strategic move that broadens Lilly's pipeline and signals long-term growth ambitions.

  • Novo Nordisk wins EU approval for oral Wegovy Novo Nordisk got EU clearance for the first oral GLP-1 pill for weight management, giving patients a pill option alongside injections. This intensifies competition for Lilly's obesity drugs in Europe, where pill preference could shift market share.

    A direct competitive threat in the key obesity market that could pressure Lilly's growth.

▲3

Lilly rides obesity-drug demand and Medicare expansion to record highs

  • JPMorgan raises price target to $1,400, stock hits record JPMorgan lifted its LLY target from $1,300 to $1,400 and reiterated overweight, citing strong demand for Mounjaro and Zepbound. The stock hit an all-time high above $1,200, with market cap surpassing $1.1 trillion. Analyst expects Q2 earnings to beat consensus.

    This is a new analyst action that directly boosted the stock and reflects confidence in future growth.

  • Lilly presents Alzheimer's data at AAIC 2026 Lilly will present 16 abstracts at the Alzheimer's conference, including new data on its Kisunla treatment and a P-tau217 blood test that could simplify diagnosis. This advances its pipeline beyond obesity, offering another long-term growth driver.

    This is a new pipeline update that shows Lilly's broader research strength beyond weight-loss drugs.

  • Canada backs Lilly's eczema drug Ebglyss Canada's drug agency gave a positive recommendation for Lilly's eczema treatment Ebglyss, which could lead to public reimbursement and wider patient access. Ebglyss is already approved in Canada and other countries, and this expands its reach.

    This is a new regulatory win that broadens Lilly's revenue base beyond obesity and diabetes.

Q2 2026
▲4

Lilly hits record on Medicare obesity coverage and cancer drug progress

  • Medicare opens obesity drugs to millions Starting July 1, Medicare's GLP-1 Bridge program offers Lilly's Zepbound and Foundayo for a flat $50 monthly copay. Up to 20 million seniors may qualify, a huge new market for obesity drugs that previously had no broad coverage.

    This is the biggest new force: a landmark policy change that expands Lilly's customer base and demand.

  • Jaypirca cancer drug advances on two fronts Europe's drug regulator recommended Jaypirca for a type of leukemia, and a Phase 3 trial showed adding it cut disease progression risk by 45%. Lilly will seek wider approvals, strengthening its cancer business beyond weight-loss drugs.

    New clinical and regulatory wins for a key cancer drug diversify Lilly's growth and support the stock.

  • Blockbuster earnings and raised guidance Lilly reported quarterly revenue of $19.8 billion, up 56% from a year ago, with Zepbound and Mounjaro contributing $12.8 billion. It raised full-year guidance to as much as $85 billion in sales and $37 in earnings per share.

    Strong financial results and higher guidance show the business is accelerating, a core reason the stock is moving.

  • Cash-rich Lilly fuels pharma deal spree A wave of drugmaker mergers in 2026, totaling $123 billion, includes Lilly using its GLP-1 cash to make bolt-on acquisitions and a $1.9 billion research deal with China's Abbisko. This helps Lilly fill its pipeline as patents expire.

    Shows how Lilly is deploying its cash to secure future growth, a strategic positive for long-term investors.

June 2026
▲4

Lilly hits record on Medicare obesity coverage and cancer drug progress

  • Medicare opens obesity drugs to millions Starting July 1, Medicare's GLP-1 Bridge program offers Lilly's Zepbound and Foundayo for a flat $50 monthly copay. Up to 20 million seniors may qualify, a huge new market for obesity drugs that previously had no broad coverage.

    This is the biggest new force: a landmark policy change that expands Lilly's customer base and demand.

  • Jaypirca cancer drug advances on two fronts Europe's drug regulator recommended Jaypirca for a type of leukemia, and a Phase 3 trial showed adding it cut disease progression risk by 45%. Lilly will seek wider approvals, strengthening its cancer business beyond weight-loss drugs.

    New clinical and regulatory wins for a key cancer drug diversify Lilly's growth and support the stock.

  • Blockbuster earnings and raised guidance Lilly reported quarterly revenue of $19.8 billion, up 56% from a year ago, with Zepbound and Mounjaro contributing $12.8 billion. It raised full-year guidance to as much as $85 billion in sales and $37 in earnings per share.

    Strong financial results and higher guidance show the business is accelerating, a core reason the stock is moving.

  • Cash-rich Lilly fuels pharma deal spree A wave of drugmaker mergers in 2026, totaling $123 billion, includes Lilly using its GLP-1 cash to make bolt-on acquisitions and a $1.9 billion research deal with China's Abbisko. This helps Lilly fill its pipeline as patents expire.

    Shows how Lilly is deploying its cash to secure future growth, a strategic positive for long-term investors.

▲4

Lilly hits record on Medicare obesity coverage and cancer drug progress

  • Medicare opens obesity drugs to millions Starting July 1, Medicare's GLP-1 Bridge program offers Lilly's Zepbound and Foundayo for a flat $50 monthly copay. Up to 20 million seniors may qualify, a huge new market for obesity drugs that previously had no broad coverage.

    This is the biggest new force: a landmark policy change that expands Lilly's customer base and demand.

  • Jaypirca cancer drug advances on two fronts Europe's drug regulator recommended Jaypirca for a type of leukemia, and a Phase 3 trial showed adding it cut disease progression risk by 45%. Lilly will seek wider approvals, strengthening its cancer business beyond weight-loss drugs.

    New clinical and regulatory wins for a key cancer drug diversify Lilly's growth and support the stock.

  • Blockbuster earnings and raised guidance Lilly reported quarterly revenue of $19.8 billion, up 56% from a year ago, with Zepbound and Mounjaro contributing $12.8 billion. It raised full-year guidance to as much as $85 billion in sales and $37 in earnings per share.

    Strong financial results and higher guidance show the business is accelerating, a core reason the stock is moving.

  • Cash-rich Lilly fuels pharma deal spree A wave of drugmaker mergers in 2026, totaling $123 billion, includes Lilly using its GLP-1 cash to make bolt-on acquisitions and a $1.9 billion research deal with China's Abbisko. This helps Lilly fill its pipeline as patents expire.

    Shows how Lilly is deploying its cash to secure future growth, a strategic positive for long-term investors.

US Dollar/Japanese Yen FX Spot Rate (USDJPY.FOREX)

Q3 2026
▲2▼2

USD/JPY hits 40-year high, then intervention and BOJ hike trigger reversal

  • USD/JPY hits 40-year high near 164 In early Q3, USD/JPY surged to a 40-year high near 164, driven by rising US yields, Fed rate hike bets, Middle East oil shocks, safe-haven dollar flows, and weak Japanese economic data.

    This is the peak event of the period and a key new development.

  • Record US-Japan intervention caps rally A record joint intervention by the US and Japan, totaling up to $96.4 billion, capped USD/JPY gains and sent the pair down to 157.95, as authorities acted to support the yen.

    This is a major new policy action that directly reversed the trend.

  • Intervention impact fades, USD/JPY rebounds The intervention's effect faded as Japanese investors bought foreign bonds and oil prices surged, lifting USD/JPY back toward 160, showing the underlying strength of dollar demand.

    This explains the rebound after intervention and is new to this period.

  • BOJ hikes to 1.25%, carry trades unwind In September, the BOJ raised rates to 1.25%, a 31-year high, triggering carry-trade unwinds that pushed USD/JPY to a seven-month low near 152.89, though Fed hikes to 3.75–4.00% and US 10-year yields above 5.2% limited yen gains.

    This is the key new monetary policy shift that drove the pair lower.

September 2026
▼3▲1

Yen hits 7-month high on BOJ hike, intervention, carry unwind

  • BOJ hikes to 31-year high The Bank of Japan raised its main interest rate to 1.25%, the highest in 31 years, and signaled more increases ahead. Higher rates make yen assets more attractive, pulling money into the yen and pushing USD/JPY lower.

    This is a major new event that directly strengthened the yen and drove USD/JPY down.

  • Record yen-buying intervention Japan spent a record $96.4 billion buying yen, with active support from the US Treasury. This massive coordinated effort forced USD/JPY down to a seven-month low near 152.89.

    This is a new, large-scale intervention that directly pushed the yen higher.

  • Carry-trade unwind A huge unwind of carry trades—where investors borrowed cheap yen to buy higher-yielding currencies—accelerated the yen's rise. As the BOJ tightened, these positions were closed, adding to yen buying.

    This is a new force that amplified the yen's appreciation during the period.

  • Fed hike and surging US yields The Fed raised rates to 3.75–4.00% and signaled more, pushing the 10-year US yield above 5.2%. Higher yields attracted money into dollars, limiting the yen's gain and even pushing USD/JPY past 157 at one point.

    This is a key counterweight that prevented a larger yen rally.

Latest
▼3▲1

BOJ tightening bets and official pushback drive yen higher

  • BOJ signals faster rate hikes, Tokyo inflation jumps BOJ September minutes showed several members backing quicker rate hikes, and Tokyo core inflation jumped to 2.7% in September from 1.8%, above forecasts. Higher Japanese rates make yen assets more attractive, strengthening the yen and pushing USDJPY down.

    This is the core new force: fresh evidence of faster BOJ tightening and hotter inflation directly strengthens the yen.

  • US and Japanese officials talk the yen up Trump and PM Takaichi both flagged the yen's weakness at their summit, and Japan's currency officials said the US and Japan sent very clear signals. The threat of official yen-buying intervention strengthens the yen and pushes USDJPY down.

    New high-level political pressure against yen weakness adds a fresh, yen-supportive force beyond central bank policy.

  • US yields surge on strong data and Fed hike bets US 10-year yields topped 5.2% and 30-year hit 5.57% as strong US PMI data and oil-driven inflation fears lifted October Fed hike odds to about 70%. Higher US rates pull money into the dollar, pushing USDJPY up.

    This is the main counterweight: rising US rates and a hawkish Fed pull the dollar up against the yen.

  • Yen carry trade unwind and fund repatriation build Strategists blamed the global bond rout on the unwinding yen carry trade, and Japanese banks sold about $70 billion of foreign bonds this year. As cheap-yen borrowing reverses and money returns home, the yen strengthens and USDJPY falls.

    It explains a structural, slow-moving flow that supports the yen and answers why the rate is moving beyond daily news.

▼3▲1

BOJ hike bets and record yen-buying intervention drive yen to 7-month high

  • BOJ signals more rate hikes ahead BOJ Deputy Governor Himino, board members Takata and Masu, and meeting minutes all pointed to further rate hikes, with Tokyo inflation accelerating and wages rising the most in nearly 30 years. Higher Japanese rates make yen assets more attractive, strengthening the yen and pushing USDJPY down.

    This is the core force behind the yen's surge this period, repeatedly confirmed by BOJ officials and data.

  • Speculators flip to net long yen, carry trades unwind For the first time since February, speculators turned net long on the yen, and the yen rallied over 7 yen in a week to a 7-month high near 152.89. Investors rushing to close carry trades (borrowing cheap yen to buy higher-yielding assets) bought back yen, pushing USDJPY down.

    This shows a major shift in market positioning that amplifies the yen's rise.

  • Japan and US officials keep up intervention pressure Finance Minister Katayama said Japan won't hesitate to coordinate intervention with the US, and Treasury Secretary Bessent told Congress the joint yen-buying was beneficial. The threat of more official yen buying strengthens the yen and pushes USDJPY down.

    Official intervention and warnings are a direct force supporting the yen.

  • US yields surge on Fed hike expectations Japan's 10-year yield hit 3.115%, a 30-year high, but US 10-year and 30-year yields jumped even more, to 5.225% and 5.502%, as markets priced a 69% chance of another Fed hike in October. Higher US rates pull money into the dollar, pushing USDJPY up.

    This is the main counterweight that could limit the yen's rise.

▲2▼2

Fed and BOJ both hike, but dollar still edges yen lower

  • Fed hikes rates for first time in over three years The Federal Reserve raised its policy rate to 3.75–4.00%, its first hike since 2023, and most officials expect another increase this year. Higher US rates make dollar assets more attractive, pulling money into the dollar and pushing USDJPY up.

    This is the main new force supporting the dollar and lifting USDJPY this period.

  • BOJ raises rate to 1.25%, highest since 1995 The Bank of Japan lifted its policy rate to 1.25%, the highest in about 31 years, and signaled more hikes ahead. Higher Japanese rates make yen assets more attractive, strengthening the yen and pushing USDJPY down.

    This is the main new force supporting the yen and weighing on USDJPY this period.

  • Yen weakens past 157 despite BOJ hike The BOJ hike was fully expected, two board members opposed it, and Japan's core inflation cooled to 1.7% in August. Traders judged the BOJ will tighten more slowly than the Fed, so the yen fell past 157 per dollar, lifting USDJPY.

    It explains why USDJPY rose even as the BOJ raised rates, a key new market reaction.

  • Japan signals possible yen-buying intervention Japan's Nikkei reported the BOJ conducted a rate check, a step before currency intervention, and the yen jumped into the 156 range. Direct yen buying strengthens the yen and pushes USDJPY down, though past interventions faded.

    It is a real counterweight that can push USDJPY down and is new this period.

▼4

Yen surges to 7-month high on BOJ hike bets and record intervention

  • BOJ rate hike to 1.25% confirmed for Sept 17-18 The Bank of Japan has decided to raise its policy rate to 1.25%, the highest in 31 years, at its September 17-18 meeting. Higher Japanese rates make yen assets more attractive, strengthening the yen and pushing USDJPY down.

    This is the single biggest new driver this period, directly strengthening the yen.

  • Yen carry trade unwinds as BOJ hawkishness builds The yen surged to 152.89 per dollar, its strongest since February, as investors rushed to close carry trades (borrowing yen to buy higher-yielding assets). Record 360 trillion yen in cross-border borrowing is unwinding, pushing the yen up and USDJPY down.

    Explains the sharp yen strengthening and why it may continue.

  • Japan's record $79.6bn reserve draw funds yen buying Japan's foreign exchange reserves fell by a record $79.6 billion in August after Tokyo spent $98.7 billion buying yen. This massive intervention directly strengthens the yen, though reserves are now limited, which could reduce future intervention power.

    Shows the scale of official yen support and its limits.

  • Bessent's Treasury buybacks and pro-yen stance US Treasury Secretary Bessent announced $6 billion in long-dated bond buybacks to lower yields and declared 'I am the house now' on the yen, coordinating with Japan to support the yen. This pulled USDJPY down from 158.89 to 153.63.

    US policy is actively pushing the yen up, a new and powerful force.

▼3

Yen surges as BOJ September hike nears and Fed holds off

  • BOJ set to hike to 1.25%, strongest yen driver The Bank of Japan is seriously considering raising its policy rate to 1.25% at its September 17-18 meeting, the highest in about 31 years, with markets now pricing a 98% chance of a hike. Higher Japanese rates make yen assets more attractive, strengthening the yen and pushing USDJPY down.

    This is the single biggest new force this period and directly explains the yen's sharp rise.

  • Waller signals Fed may hold, dollar weakens Fed Governor Waller said the Fed 'can wait one meeting' and should 'give disinflation a chance,' cutting September hike odds from 63% to about 50%. Lower expected US rates reduce the dollar's appeal, weakening the dollar and pushing USDJPY down.

    A new shift in US rate expectations is the other half of the narrowing US-Japan rate gap.

  • Yen jumps past 160 to mid-155 on suspected BOJ intervention The yen surged about 2.5% from 158.5 to 155.4, with analysts pointing to another BOJ intervention after Japan's record 15.4 trillion yen ($98 billion) yen-buying effort. Direct yen buying strengthens the yen and pushes USDJPY down, though intervention effects have faded before.

    A fresh, large intervention-scale move is a direct driver of the rate's sharp drop.

  • Japan 10-year yield hits 3%, but oil and fiscal worries cut both ways Japan's 10-year bond yield reached 3% for the first time in 30 years on BOJ hike bets, drawing money into yen and pushing USDJPY down. But Middle East clashes lifted oil above $96, hurting Japan's import-heavy economy, and a record 36.6 trillion yen debt-servicing budget fuels fiscal worries that can weaken the yen.

    It shows the real counterweight: higher yields support the yen, but oil and fiscal risk work against it.

August 2026
▼2▲1

Record Yen-Buying Intervention Battles Persistent Dollar Strength

  • Record US-Japan intervention Japan spent a record $96.4bn buying yen, with US Treasury Secretary Bessent's aggressive support, pushing USD/JPY down. This unprecedented campaign initially strengthened the yen.

    It was the main new force driving USD/JPY lower in August.

  • Weak US jobs and BOJ hike bets Weak US jobs data and expectations that the Bank of Japan will hike rates in September also weighed on USD/JPY, as a BOJ hike would make yen assets more attractive.

    These factors added downward pressure on USD/JPY during the period.

  • Intervention impact fades The intervention's effect faded as Japanese investors kept buying foreign bonds, oil surged on the closed Strait of Hormuz, and rising long-term US and Japanese yields supported the dollar, lifting USD/JPY back toward 159–160.

    It explains why USD/JPY rebounded despite the record intervention.

  • Fed hike hint vs BOJ caution Fed Chair Warsh hinted at a September hike, briefly lifting USD/JPY to 160. But if the BOJ turns cautious on weak GDP, yen weakness could accelerate; a BOJ hike would strengthen the yen.

    It highlights the two-sided risks that kept USD/JPY volatile.

▼2▲1

Record Japan-US yen buying vs Fed hike talk keeps USDJPY whipsawing

  • Japan's record $96bn yen-buying intervention Japan spent a record 15.4 trillion yen ($96.4 billion) between July 30 and August 26 to buy yen and sell dollars, with US support. This directly strengthens the yen and pushes USDJPY down, though the effect fades as investors keep selling yen.

    The record scale of intervention is the biggest new fact shaping the yen's floor and directly answers what is driving USDJPY.

  • Fed Chair Warsh hints at rate hike, dollar jumps to 160 yen Fed Chair Warsh said rates may need to rise to fight inflation, lifting the chance of a September hike to about 58% from 35%. Higher US rates make the dollar more attractive, pushing USDJPY up toward 160.

    This is the newest force pushing the dollar up and explains why USDJPY recovered to 160 despite intervention.

  • BOJ September rate hike expected, narrowing rate gap Markets expect the Bank of Japan to raise rates at its September 18 meeting, with the 10-year Japanese yield near 3%, the highest since the mid-1990s. Higher Japanese rates make the yen more attractive, working against USDJPY rising.

    The BOJ's expected hike is a key counterweight to dollar strength and a main reason USDJPY may not keep climbing.

  • US Treasury buybacks and Bessent's warning cut both ways The US Treasury expanded long-term bond buybacks, pulling US yields down and strengthening the yen to about 158. But Bessent warned disorderly yen moves could raise US rates, keeping the US ready to support the yen again.

    These policy moves show the two-way tug on USDJPY: lower US yields help the yen, while US readiness to intervene caps yen weakness.

▲2▼1

Yen weakness persists despite historic US-Japan intervention

  • Historic US-Japan joint yen-buying intervention Japan and the US jointly bought yen in early August, the first coordinated action since 1998, with Japan possibly spending up to $59 billion in one day. This directly strengthens the yen and pushes USDJPY down, though the effect has faded.

    This is the biggest new force this period, directly pushing USDJPY down.

  • Intervention impact fades; yen slips back After touching 155.23 per dollar, the yen weakened back to around 159.60 as the intervention's effect faded and no further action followed. Japanese investors kept buying foreign bonds, keeping money flowing out of the yen, so the downward push on USDJPY may not last.

    Shows the counterweight: intervention gains are being erased, allowing USDJPY to rise again.

  • Rising long-term yields and fiscal worries support dollar Japan's 10-year yield hit a 30-year high of 2.945% and the US 30-year reached 5.3%, a 19-year high, on concerns about Japan's fiscal situation and higher oil prices. Higher long-term yields pull money into the dollar and out of the yen, pushing USDJPY up.

    This is a new driver this period that supports USDJPY despite intervention.

  • Bessent pushes for coordinated intervention plus BOJ hike Treasury Secretary Bessent, now the most interventionist in decades, wants Japan to combine yen-buying with a BOJ rate hike. A BOJ hike would strengthen the yen, but if the BOJ turns cautious because of weak GDP, yen weakness could gain momentum.

    This new policy stance could either strengthen or weaken the yen, making it a key uncertainty.

▲2▼2

Yen stays weak as intervention fades and BOJ September hike looms

  • Weak US jobs data cuts Fed hike odds, dollar falls July US payrolls unexpectedly fell by 23,000, the first drop in five months, and wage growth slowed. Markets now see only about a 44% chance of a September Fed rate hike, down from 58%. Lower US rate expectations weaken the dollar and strengthen the yen, pushing USDJPY down.

    This is the main new US-side force this period, directly lowering the dollar's appeal versus the yen.

  • BOJ signals possible September rate hike The Bank of Japan may raise rates as early as its September 17-18 meeting, its first hike in three months, as July wholesale prices rose 7.2% and weak yen fuels inflation. Higher Japanese rates make the yen more attractive, strengthening it and pushing USDJPY down.

    A BOJ hike is the biggest new yen-supporting force and a key counterweight to yen weakness.

  • Intervention effect fades; yen slips back past 159 The yen weakened back to about 159 per dollar, erasing a quarter of the gains from the roughly $88 billion joint intervention ten days earlier. Japanese investors kept buying foreign bonds, keeping money flowing out of the yen. This shows the intervention's downward push on USDJPY may not last.

    It shows the earlier intervention is losing force, a real counterweight to the yen-strengthening story.

  • Oil surge and weak yen push long-term yields higher Brent crude jumped 5% to near $90 as the Strait of Hormuz stayed closed, and the yen weakened past 159. Higher oil hurts Japan, which imports almost all its oil, and rising long-term US yields pull money into the dollar, both pushing USDJPY up.

    Oil and yield moves are a fresh upward force on USDJPY this period.

▼3▲1

US-Japan joint yen-buying intervention drives USDJPY down; weak US jobs add pressure

  • Historic US-Japan joint intervention The US and Japan jointly bought yen in late July and early August, the first coordinated action since 1998. Japan may have spent up to $59 billion in one day. This directly strengthens the yen and pushes USDJPY down.

    This is the dominant new force driving USDJPY lower this period.

  • US Treasury signals more yen buying Treasury Secretary Bessent called the yen 'very undervalued' and said the US will not hesitate to join further intervention. The US also proposed expanding a Fed facility so Japan can get dollars without selling US Treasuries. This keeps pressure on USDJPY.

    It shows official US support for a stronger yen, a key driver of the rate.

  • Weak US jobs data cuts Fed hike odds US payrolls fell by 23,000 in July, far below expectations. Markets now see a 56% chance the Fed holds rates in September, up from 45%. Lower US rate expectations weaken the dollar and push USDJPY down.

    It directly reduces the dollar's yield appeal, a main support for USDJPY.

  • Intervention impact fades; yen slips back The yen has weakened back to 158.45 per dollar after touching 155.23, surrendering nearly half its gains. Analysts see more intervention likely if the yen approaches 160. This shows the downward push may not last.

    It provides a fair counterweight: the intervention's effect is already fading.

July 2026
▲2▼2

USD/JPY Hits 40-Year High, Then Plunges on Record Intervention

  • US yields and Fed hike bets lift dollar Rising US bond yields and strong expectations of Fed rate hikes made the dollar more attractive, pushing USD/JPY to a 40-year high near 164.

    This explains the main upward force on USD/JPY during the period.

  • Oil shock and safe-haven demand support dollar Middle East oil shocks and safe-haven flows boosted the dollar, while weak Japanese data and fiscal worries weighed on the yen, adding to USD/JPY gains.

    These factors contributed to the dollar's strength and yen's weakness.

  • Rising Japanese yields and BOJ hike bets cap gains Japan's 10-year yield hit a 29-year high, raising carry-trade costs, and BOJ rate-hike expectations grew, limiting further USD/JPY upside.

    This counterweight prevented even larger gains before the intervention.

  • Record intervention and Fed hold slam USD/JPY Japan intervened massively (up to $59 billion), with possible US support, sending USD/JPY from 163.65 to 157.95; a Fed hold and weak US GDP added downward pressure.

    This was the major event that reversed the pair's rise late in the month.

▼4

Japan and US intervene to rescue yen from 40-year low

  • Japan's massive yen-buying intervention Japan intervened in New York on July 30, buying yen and selling dollars, possibly up to $59 billion. The yen surged from 163.65 to 157.95 in 50 minutes, its biggest daily gain since 2022. This directly strengthens the yen and pushes USDJPY down.

    This is the single biggest new force this period, directly reversing the yen's weakness.

  • US Treasury signals it may join intervention The US Treasury told banks through the New York Fed it may intervene in the yen market, and Japan and South Korea staged a rare joint intervention with US support. US backing makes the yen-buying effort more powerful and credible, pushing USDJPY down.

    US involvement is a new escalation that amplifies the intervention's impact on USDJPY.

  • Fed holds rates, weak US GDP, dovish tilt The Fed kept rates at 3.50-3.75% for the fifth straight time, with three members wanting a hike. US second-quarter GDP grew only 1.5%, missing forecasts. This reduces the US-Japan rate gap appeal, weakening the dollar and pushing USDJPY down.

    A less hawkish Fed and weak growth remove a key support for the dollar, helping the yen.

  • BOJ keeps door open for faster rate hikes The BOJ held rates at 1% but signaled readiness to hike again, with a professor saying it could move to quarterly hikes if wages stay strong. Higher Japanese rates would make the yen more attractive, working against USDJPY rising.

    BOJ hawkishness is a persistent counterweight to yen weakness, now reinforced by intervention.

▲3▼1

Oil shock and Fed hike bets drive yen to 40-year low

  • Oil spike on Middle East conflict lifts dollar and sinks yen Brent crude topped $100 after Houthi attacks on Saudi tankers and US-Iran strikes. Higher oil raises US inflation expectations, boosting Fed rate-hike bets and dollar demand, while it hurts Japan, which imports almost all its oil. USDJPY rose to near 164, a 40-year high.

    The dominant new force this period pushing USDJPY up.

  • Fed rate-hike odds jump, widening the US-Japan rate gap Markets now price an 83% chance of a September Fed hike, up from about 52% a week earlier, and the US 10-year yield hit 4.70%, its highest since January 2025. Higher US rates pull money into the dollar and out of the low-yielding yen, pushing USDJPY up.

    Core monetary driver of dollar strength versus yen.

  • BOJ signals it may hike faster; Japan warns on intervention The BOJ is reportedly open to raising rates faster than the market expects, and Finance Minister Katayama repeated readiness to act 'decisively' as the yen passed 163. Both strengthen the yen and cap USDJPY, though they have not reversed the uptrend.

    The main counterweight working against further USDJPY gains.

  • Japan fiscal worries and weak trade data add to yen selling DoubleLine warned Japan's unfunded spending risks a UK-style bond revolt, and Japan's June trade deficit widened to ¥406.9 billion as imports hit a record. Both undermine confidence in Japanese assets and the yen, supporting USDJPY.

    New fiscal and trade factors adding downward pressure on the yen.

▲3▼1

Yen slides on pension doubts and oil spike; Fed-BOJ hike race caps losses

  • Japan pension fund overhaul doubts weaken yen A Reuters report said Japan has no immediate plan to change its state pension funds' asset allocations, reducing demand for yen. With less yen buying from Japan's huge pension savings, the yen weakens and USDJPY rises.

    This is a new, specific driver that weakens the yen and pushes USDJPY up.

  • Middle East oil spike and safe-haven dollar demand US-Iran tensions escalated with attacks and a Strait of Hormuz blockade, pushing crude oil up 9%. Investors bought dollars as a safe haven, while higher oil prices hurt Japan's import-heavy economy, both pushing USDJPY higher.

    New escalation this period directly boosts dollar demand and weakens yen via oil.

  • Hawkish Fed comments and rising US yields support dollar Fed officials made hawkish remarks and the US 10-year yield rose to 4.63%, a two-month high. Higher US yields make dollar deposits more attractive, pulling money into the dollar and pushing USDJPY up.

    New hawkish Fed signals and yield spike this period strengthen the dollar.

  • BOJ rate hike expectations and bond-buying talk cap yen weakness Japan's inflation is strong, with about 70% odds of a BOJ rate hike by October. A former BOJ board member said the government may ask the BOJ to buy more bonds if long-term rates exceed 3%, which would weaken the yen, but the hike path supports the yen and limits USDJPY gains.

    This is the main counterweight: BOJ tightening expectations strengthen the yen and cap USDJPY.

▲2▼1

Yen slides to 162 as US yields and oil spike, Japan yields cap gains

  • US 10-year yield hits 4-week high, supporting dollar The US 10-year Treasury yield rose to 4.58%, a four-week high, after hawkish Fed minutes and rising oil prices. Higher US yields make dollar deposits more attractive, pulling money into the dollar and pushing USDJPY up.

    Directly explains the dollar's yield advantage that keeps USDJPY elevated.

  • Middle East oil spike and safe-haven dollar demand US-Iran tensions escalated with strikes near the Strait of Hormuz, pushing crude oil up 3% and stocks down. Investors bought dollars as a safe haven, while higher oil prices hurt Japan's import-heavy economy, both pushing USDJPY higher.

    New geopolitical shock that boosts dollar demand and weighs on the yen.

  • Japanese 10-year yield hits 29-year high, raising carry-trade costs Japan's 10-year bond yield briefly hit 2.86%, the highest since 1997, as the BOJ trims bond buying and fiscal worries grow. Higher Japanese yields make the yen more attractive to hold and raise the cost of borrowing yen to fund dollar purchases, working against USDJPY rising.

    Key counterweight that could slow or reverse yen weakness.

Q2 2026
▲2▼2

Hawkish Fed and Weak Yen Drive USD/JPY Higher Despite BOJ Tightening

  • Hawkish Fed under new chair Kevin Warsh The Federal Reserve, under new chair Kevin Warsh, took a hawkish stance, boosting expectations for interest rate hikes. This strengthened the US dollar against the yen as investors anticipated higher returns on dollar assets.

    This is a key new factor driving the dollar higher.

  • Surging Fed hike bets Market bets on Fed rate hikes surged, pushing US bond yields up and attracting capital to the dollar. The yen weakened further as the interest rate gap between the US and Japan remained wide, encouraging carry trades.

    This reinforces the dollar's strength and yen's weakness.

  • BOJ hike to 1% and faster tightening signals The Bank of Japan raised its policy rate to 1%, the highest since 1995, and signaled faster tightening ahead. This acted as a counterweight, limiting USD/JPY gains by narrowing the rate differential and supporting the yen.

    This is a major counterforce to the dollar's rise.

  • Record ¥11.73 trillion intervention and warnings Japan conducted a record ¥11.73 trillion currency intervention and issued repeated warnings, capping USD/JPY gains. These actions created downside risks and limited further yen weakness.

    This directly countered upward pressure on USD/JPY.

June 2026
▲2▼2

Hawkish Fed and Weak Yen Drive USD/JPY Higher Despite BOJ Tightening

  • Hawkish Fed under new chair Kevin Warsh The Federal Reserve, under new chair Kevin Warsh, took a hawkish stance, boosting expectations for interest rate hikes. This strengthened the US dollar against the yen as investors anticipated higher returns on dollar assets.

    This is a key new factor driving the dollar higher.

  • Surging Fed hike bets Market bets on Fed rate hikes surged, pushing US bond yields up and attracting capital to the dollar. The yen weakened further as the interest rate gap between the US and Japan remained wide, encouraging carry trades.

    This reinforces the dollar's strength and yen's weakness.

  • BOJ hike to 1% and faster tightening signals The Bank of Japan raised its policy rate to 1%, the highest since 1995, and signaled faster tightening ahead. This acted as a counterweight, limiting USD/JPY gains by narrowing the rate differential and supporting the yen.

    This is a major counterforce to the dollar's rise.

  • Record ¥11.73 trillion intervention and warnings Japan conducted a record ¥11.73 trillion currency intervention and issued repeated warnings, capping USD/JPY gains. These actions created downside risks and limited further yen weakness.

    This directly countered upward pressure on USD/JPY.

▼3▲1

Yen hits 40-year low on Fed hike bets, then rebounds on weak US jobs

  • Fed rate hike bets and wide rate gap push yen to 40-year low Traders fully expect at least one Fed rate hike by year-end, with core inflation at its highest since 2023. Because US rates are far above Japan's, investors borrow yen cheaply to buy dollars, pushing USDJPY up to 162.68.

    This is the main force driving USDJPY higher this period.

  • Weak US jobs report slashes Fed hike odds, yen surges June payrolls added only 57,000 jobs, far below the 110,000 expected. The chance of a September Fed hike fell to 53% from 67%, weakening the dollar and strengthening the yen, with USDJPY dropping to 160.97.

    This is the key new counterweight that reversed the dollar's rise.

  • BOJ signals earlier rate hike as economy strengthens The BOJ's Tankan survey showed business confidence at an eight-year high, and markets now see over 60% odds of a rate hike by October. Higher Japanese rates would make the yen more attractive, working against USDJPY rising.

    This is a new fundamental factor that could strengthen the yen going forward.

  • Japan intervention threat caps yen weakness Japan's finance minister repeatedly warned of bold action as the yen passed 162 per dollar. Traders are on high alert for intervention, and Reuters reported a more aggressive strategy, which limits further USDJPY gains.

    This is a real counterweight that prevents the yen from falling further.

▲2▼2

Yen pinned near 40-year low as Fed hike bets and BOJ caution dominate

  • Fed rate hike expectations surge Traders now see a 54% chance of at least two Fed rate hikes by year-end, up from 15% a week ago. Higher US rates make the dollar more attractive to hold, pushing USDJPY up.

    This is the main new force driving the dollar higher against the yen this period.

  • Yen nears 40-year low despite BOJ hike The yen weakened to 161.87 per dollar, just shy of its weakest since 1986, even after the BOJ raised rates to 1%. The rate gap with the US remains wide, keeping the yen weak and USDJPY high.

    Shows the yen's persistent weakness despite BOJ tightening, a key driver of USDJPY.

  • Japan's record yen intervention Japan spent a record ¥11.73 trillion ($73.4 billion) through late May to support the yen, likely selling US Treasuries. This intervention strengthens the yen and works against USDJPY rising, though it hasn't reversed the trend.

    This is a real counterweight that could cap USDJPY gains, important for a balanced view.

  • BOJ official hints at faster rate hikes BOJ board member Naoki Tamura said the central bank should hike rates every few months toward 2%. This signals a tighter Japanese monetary policy ahead, which could strengthen the yen and push USDJPY down.

    A new hawkish BOJ signal that could shift the interest rate gap and yen direction.

▲2▼1

Hawkish Fed and BOJ hike push yen to two-year low

  • Fed turns hawkish under new chair, boosting USD The Federal Reserve, under new chair Kevin Warsh, kept rates steady but signaled it may hike later this year, with nearly half of officials now expecting a hike. This makes the dollar more attractive to hold, strengthening it against the yen and pushing USDJPY higher.

    This is the main new force driving the dollar up and the yen down this period.

  • Bank of Japan raises rates to 1%, highest since 1995 The Bank of Japan raised its policy rate from 0.75% to 1%, the highest since 1995, and will keep reducing bond purchases. Higher Japanese rates make the yen more attractive to hold, which works against USDJPY rising and is a real counterweight to dollar strength.

    This is the main new force supporting the yen and opposing the dollar's rise.

  • Yen carry trade remains heavy despite BOJ hike Even after the BOJ hike, Japanese rates are still far below those in the US, so investors continue borrowing yen cheaply to buy higher-yielding currencies. Leveraged funds hold their largest bearish yen position since 2017, keeping downward pressure on the yen and pushing USDJPY up.

    Explains why the yen stays weak even as the BOJ tightens, a key reason USDJPY keeps rising.

  • Japan warns on yen weakness, intervention risk caps gains Japan's government warned it is ready to act against excessive currency moves as the yen hit a two-year low past 161 per dollar. The threat of intervention can slow or reverse USDJPY's rise, but so far it has only slowed the move, not stopped it.

    This is the main risk that could push USDJPY down and is a real counterweight to the dollar's rise.

© 2026 MarketIVWhy